{
    "clinical_study": {
        "@rank": "18369", 
        "acronym": "LYMPHCORD", 
        "arm_group": {
            "arm_group_label": "Cord blood transplantation", 
            "arm_group_type": "Experimental", 
            "description": "Two cord blood units containing both together more than 3x10^7 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients."
        }, 
        "brief_summary": {
            "textblock": "Indication: Patients with advanced lymphoid malignancies in the absence of an HLA identical\n      or mismatch donor.\n\n      Objectives: Overall survival at one year. Efficacy >60%, rejection rate <20%. Inclusion\n      criteria: Age: 18-65 years old, no sibling or unrelated donor identified, low grade\n      non-hodgkin lymphoma in third line (who already received at least one autologous\n      transplantation); hodgkin lymphoma in early relapse (<1 year), who received at least one\n      autologous transplantation and sensible to chemotherapy and CLL with 17p deletion or in\n      relapse less than 2 year after a fludarabine nbased regimen or in relapse after one\n      autologous transplantation.\n\n      Stem cell source: Two cord blood units containing both together more than 3x107 frozen\n      nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the\n      patients."
        }, 
        "brief_title": "Cord Blood Transplantation in Patients With Advanced Lymphoid Malignancies", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Patients With Advanced Lymphoid Malignancies in the Absence of an HLA Identical or Mismatch Donor", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: 18-65 years old\n\n          -  no sibling or unrelated donor identified (9/10 or 10/10)\n\n          -  with either one of these advanced lymphoid malignancies\n\n               1. low grade non-hodgkin lymphoma in third line (who already received at least one\n                  autologous transplantation)\n\n               2. hodgkin lymphoma in early relapse (<1 year)who received at least one autologous\n                  transplantation and sensible to chemotherapy\n\n               3. CLL with 17p deletion or in relapse less than 2 year after a fludarabine nbased\n                  regimen or in relapse after one autologous transplantation.\n\n        Exclusion Criteria:\n\n          -  No patient signed consent\n\n          -  Previous allograft\n\n          -  Psychiatric conditions\n\n          -  HIV positive\n\n          -  HVC hepatitis requiring treatment\n\n          -  Previous total body irradiation (TBI)\n\n          -  Any contraindication to TBI\n\n          -  Any contraindication to allograft, such as cardiovascular, respiratory, renla or\n             liver dysfunctions\n\n          -  No Health care insurance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01966510", 
            "org_study_id": "P110145"
        }, 
        "intervention": {
            "arm_group_label": "Cord blood transplantation", 
            "intervention_name": "Cord Blood Transplantation", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "cord blood transplant", 
            "advanced lymphoid malignancies"
        ], 
        "lastchanged_date": "April 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "zip": "75010"
                }, 
                "name": "Saint Louis hospital"
            }, 
            "investigator": {
                "last_name": "Regis Peffault de Latour, MD PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective Phase II Study to Evaluate Cord Blood Transplantation in Patients With Advanced Lymphoid Malignancies.", 
        "overall_contact": {
            "email": "regis.peffaultdelatour@sls.aphp.fr", 
            "last_name": "Regis Peffault de Latour, MD PhD", 
            "phone": "33 1 42 38 50 73"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01966510"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Neutrophils > 500/mm3 and platelets > 20 Giga/L", 
                "measure": "Engraftment", 
                "safety_issue": "No", 
                "time_frame": "100 days"
            }, 
            {
                "description": "using PCR", 
                "measure": "Chimerism", 
                "safety_issue": "No", 
                "time_frame": "D15, D30, D60, D100, M6, M12 and M24"
            }, 
            {
                "measure": "Acute Graft versus host disease (GvHD)", 
                "safety_issue": "No", 
                "time_frame": "100 days"
            }, 
            {
                "measure": "Chronic graft versus host disease (GVHD)", 
                "safety_issue": "No", 
                "time_frame": "within 2 years after inclusion"
            }, 
            {
                "description": "phenotypic measurements of lymphocyrtes populations (T, B and NK)", 
                "measure": "Immunologic reconstitution", 
                "safety_issue": "No", 
                "time_frame": "D30, D60, D100, M6, M12 and M24"
            }, 
            {
                "description": "defined using criteria from EBMT (Cordonnier, www.ebmt.org)", 
                "measure": "Incidence of severe infectious complications", 
                "safety_issue": "Yes", 
                "time_frame": "D100 and M12"
            }, 
            {
                "measure": "Relapse rate", 
                "safety_issue": "No", 
                "time_frame": "within the 2 years after inclusion"
            }, 
            {
                "measure": "Relapse free survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "recorded according to OMS grading scale", 
                "measure": "toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}